Consensus Herantis Pharma Oyj

Equities

HRTIS

FI4000087861

Market Closed - Nasdaq Helsinki Other stock markets 17:00:00 28/06/2024 BST			5-day change	1st Jan Change
1.66 ^EUR	+1.84%		+0.30%	+5.40%

05-20	Herantis Pharma Submits Clinical Trial Application for A Phase 1B Clinical Trial of Her-096	CI
03-06	Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Herantis Pharma Oyj

Price target over the last 5 years

History of analyst recommendation changes

55714969ac662a0c534fda17af8a.G_mqoCcNVF19A7WCYDbnuZ9NY5wur4JLxWWYQFpJ1TU.UKGc-hQ5MDxQNdfrCXukwe91UtFY2ec8j1fPEhc_ln5EwcbvT2sfEFBw4A~6c0fa7ccf55eac02cf8ceb12a4b9a0c1

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.66 EUR

Average target price

2.55 EUR

Spread / Average Target

+53.61%

High Price Target

2.9 EUR

Spread / Highest target

+74.70%

Low Price Target

2.2 EUR

Spread / Lowest Target

+32.53%

Consensus detail

Consensus revision (last 18 months)

Annual profits - Rate of surprise

Company calendar